GLP‐1: A Prospective Guardian for Comprehensive Myocardial Perfusion

Abstract

ObjectiveTo investigate the role of glucagon‐like peptide 1 (GLP‐1) in myocardial perfusion, focusing on its effects on coronary microcirculation and cardiovascular outcomes.MethodsReview of foundational research and large‐scale clinical trials, including Cardiovascular Outcome Trials (CVOTs), examining the cardiovascular effects of GLP‐1. Systematic analysis of trial data to assess the impact of GLP‐1 therapy on myocardial infarction, composite cardiovascular events, and stroke incidence.ResultsGLP‐1 therapy was found to significantly reduce myocardial infarction and composite cardiovascular events. Additionally, GLP‐1 receptor agonists were observed to reduce stroke incidence, suggesting systemic effects on panvascular diseases. While direct protective effects on coronary microvasculature have been less studied, growing evidence supports GLP‐1's role in comprehensive myocardial perfusion.ConclusionGLP‐1 is a promising therapeutic agent for improving myocardial perfusion and reducing cardiovascular events. Its protection is likely associated with comprehensive improvements in myocardial perfusion, including effects on coronary microcirculation. Further research is needed to fully elucidate its mechanisms of action and potential clinical applications.